Barbiturate Drug Class Medications
Barbiturates are derivatives of barbituric acid classified into long-acting and short-acting agents, with currently licensed medications including phenobarbital (long-acting) and pentobarbital (short-acting), while intermediate-acting agents like butobarbital, secobarbital, and amobarbital are no longer licensed in most developed countries. 1
Classification by Duration of Action
Barbiturates are pharmacologically categorized based on their duration of action:
Long-Acting Barbiturates
- Phenobarbital (representative agent)
- Elimination half-life: 80-120 hours
- Duration of action: 6-12 hours
- 20-25% excreted unchanged in urine
- Less lipid soluble with smaller volume of distribution (0.25-1.2 L/kg) 1
Short-Acting Barbiturates
- Pentobarbital (representative agent)
- Elimination half-life: 15-48 hours
- Duration of action: 3-4 hours
- <5% excreted unchanged in urine
- More lipid soluble with larger volume of distribution (0.5-1.0 L/kg) 1
Intermediate-Acting Barbiturates (No Longer Licensed)
The following are no longer licensed for use in the United States, United Kingdom, and most developed countries, and can only be prescribed to patients already taking them for intractable insomnia:
- Butobarbital
- Secobarbital
- Amobarbital 1
Additional Barbiturates Identified in Literature
Research studies have documented numerous other barbiturate compounds, though their current clinical availability varies:
- Barbital
- Butalbital
- Butabarbital
- Thiopental
- Methohexital
- Hexobarbital
- Mephobarbital
- Aprobarbital
- Allobarbital
- Cyclobarbital 2, 3, 4
Key Clinical Considerations
All barbiturates share common pharmacological properties: they are hepatic CYP450 enzyme inducers, undergo hepatic metabolism as their primary clearance route, and cause CNS depression with potential for respiratory and cardiovascular suppression 1.
Important Caveats
Tolerance develops to sedative effects but NOT to lethal serum concentrations - long-term users can tolerate higher doses but remain at risk of fatal toxicity at the same serum levels as naive users 1
Dangerous synergy with other CNS depressants - when combined with alcohol, opiates, or benzodiazepines, overdose risk increases dramatically due to additive respiratory and CNS depression 1
Pentobarbital remains clinically available and is also used in veterinary practice, making it accessible for intentional poisoning 1